Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes.
about
Current Trends in Development of Liposomes for Targeting Bacterial BiofilmsInhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.Nanomedicine in the Management of Microbial Infection - Overview and PerspectivesNanoparticle approaches against bacterial infectionsBaicalein attenuates the quorum sensing-controlled virulence factors of Pseudomonas aeruginosa and relieves the inflammatory response in P. aeruginosa-infected macrophages by downregulating the MAPK and NFκB signal-transduction pathways.In vitro and in vivo activities of ticarcillin-loaded nanoliposomes with different surface charges against Pseudomonas aeruginosa (ATCC 29248)Bismuth compounds in medicinal chemistry.Materials innovation for co-delivery of diverse therapeutic cargos.Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.Bisphosphocins: novel antimicrobials for enhanced killing of drug-resistant and biofilm-forming bacteria.Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients.Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.Toward an optimized treatment of intracellular bacterial infections: input of nanoparticulate drug delivery systems.Ginseng aqueous extract attenuates the production of virulence factors, stimulates twitching and adhesion, and eradicates biofilms of Pseudomonas aeruginosa.Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa.Nanotechnology-based drug delivery systems for control of microbial biofilms: a review.Importance of Biofilms in Urinary Tract Infections: New Therapeutic Approaches
P2860
Q26865495-45DACAC7-259E-46A7-A922-EF4145BFC182Q28077482-5BFD2D68-885D-4F1A-9A29-63B69D8EC618Q34245494-72F96262-5B16-49AC-B451-47D07B0BFD1EQ34339159-6AA0DF6C-4CAA-417F-82EA-F9BC48B34C7AQ34675340-BF8669A5-EBF9-4A88-8B86-D80EB76EC0EAQ36564740-E2501376-37E2-4FD2-88A3-6FE45E9C6EAAQ38031636-B415682F-0889-4497-8B2D-D0DFE7E6DFE7Q38211033-26E4990F-CA27-4C51-AC5B-009F3C1F9C5BQ38214155-234DD0A6-B4FE-47A3-A249-E3DB552068B3Q38644506-8E0C1F74-4762-4075-9A5B-39400201594AQ38938501-B0EBE654-F72A-4BB3-9E5E-427546E1E32EQ39172960-2A4FA1BA-AF5B-4BAC-A905-5DEB37A72E0AQ40974806-3C0F8C07-8B2A-4F0E-99ED-2CD72FFC6CF0Q44573552-42196D8B-E342-42E7-B40A-2D9A2A2B41DEQ44861090-471219F3-59AB-48C2-8E4D-0D63DEE92C81Q52362285-229A8771-DFD6-4762-BBC5-F4A6DFACC484Q59042611-82643590-036B-49D0-B8ED-75B947F058E0
P2860
Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Attenuation of Pseudomonas aer ...... with tobramycin in liposomes.
@en
Attenuation of Pseudomonas aer ...... with tobramycin in liposomes.
@nl
type
label
Attenuation of Pseudomonas aer ...... with tobramycin in liposomes.
@en
Attenuation of Pseudomonas aer ...... with tobramycin in liposomes.
@nl
prefLabel
Attenuation of Pseudomonas aer ...... with tobramycin in liposomes.
@en
Attenuation of Pseudomonas aer ...... with tobramycin in liposomes.
@nl
P2093
P2860
P356
P1476
Attenuation of Pseudomonas aer ...... with tobramycin in liposomes.
@en
P2093
Abdelwahab Omri
Misagh Alipour
Robert M Lafrenie
Zacharias E Suntres
P2860
P304
P356
10.1093/JAC/DKQ036
P407
P577
2010-02-15T00:00:00Z